ProQR Therapeutics N.V. announced the appointment of Dr. Peter A. Beal as its Chief ADAR Scientist. Dr. Beal, a professor of Chemistry at the University of California, Davis, is recognized as a leading expert in ADAR and RNA biology and chemistry.
Dr. Beal has been a long-term collaborator and a member of ProQR’s Scientific Advisory Board, contributing significantly to the development of the company's ADAR-based RNA editing platform. In his new role, he will expand his contributions by driving the development and optimization of the Axiomer platform.
His responsibilities will include overseeing platform optimization, scientific developments in editing oligonucleotide design, advancing preclinical development efforts, and expanding the company’s therapeutic pipeline. This appointment is expected to strengthen ProQR's position in ADAR-mediated RNA-editing innovation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.